News

Experts Explain What Today’s Resounding Decision to Uphold the ACA Means for Millions of Families Nationwide

Historic Victory for the American People a Final Repudiation of Trump-Republican War on Health Care

Listen to the Call Here

Washington, DC — Today, U.S. Senator Bob Casey (D-PA), former HHS Secretary Kathleen Sebelius, and Supreme Court expert Andy Pincus joined Protect Our Care to react to the Supreme Court decision in California v. Texas, the Trump-Republican lawsuit to overturn the Affordable Care Act. In an 7-2 ruling, the Supreme Court delivered a massive repudiation to the Republican war on health care. By throwing the Trump-backed lawsuit out on standing, the court protected the health care coverage of more than 20 million Americans, prevented more than 135 million people with pre-existing conditions from losing the protections they rely on, and reaffirmed dozens of other important provisions of the landmark health care law. 

Today’s decision should mean the end of the road for Republicans’ endless attacks on the law and increases the momentum behind President Biden’s and the Democratic majorities in Congress to deliver on their health care agenda: building on the ACA to lower health care and drug costs, increase coverage, and reduce disparities in health care. 

“Republicans in Congress and far right Attorneys General have once again failed in their attempt to rip health care away from millions of Americans and decimate Medicaid,” said U.S. Senator Bob Casey (D-PA). “It’s past time for those Republicans who keep bringing these frivolous lawsuits finally to stop these attacks on affordable health care. It’s time to make the changes in the American Rescue Plan permanent and build on the Affordable Care Act to expand coverage and bring down costs for working families.”

“It’s a very important day for Americans,” said former HHS Secretary Kathleen Sebelius. “We’re in the middle of open enrollment, and what we know is more people than ever before are signing up — reaffirming the importance of both the marketplaces across this country and Medicaid expansion. The ACA has transformed the lives of over 31 million people. I think that the decision today will give confidence to folks who may have been hesitant that they should indeed take advantage of the wonderful improvements made to the ACA in the Biden administration. I hope we all roll up our sleeves and from now until August 15 make sure we get the word out loud clearly that the ACA is very much alive and well. This is a very, very good day.” 

“For the third time, the Supreme Court upheld the Affordable Care Act and its protections for millions of Americans. First the court upheld the law 5-4, then 6-3, and now 7-2 – making clear that the ACA is the law of the land,” said Supreme Court expert Andy Pincus. “The bottom line here is that the Court’s decision sends a clear message that the ACA is alive and well. The time for legal challenges for the Affordable Care Act is over.” 

“Today’s decision proves what legal experts and scholars have warned from the beginning: this was a bogus lawsuit driven by nothing other than Republicans’ animosity for affordable health care. Donald Trump and Republican lawmakers have been relentless in their quest to overturn the ACA, and when they failed to do so in Congress, they turned to this illegitimate effort to rip health care away from tens of millions of Americans,” said Protect Our Care Executive Director Brad Woodhouse. “Once and for all, Republicans can put their war on health care to rest. The ACA is here to stay.” 

“Today marks a historic victory for the American people. Once again, the Supreme Court has ruled that the ACA is the law of the land — a final repudiation of the Republican war on health care. Repeal is dead, the ACA is widely popular, and people are relying on the law now more than ever,” said Protect Our Care Chair Leslie Dach. “Now 31 million people can rest knowing that their health care is protected, and President Biden and Congress can work to meet the demands of voters across the political spectrum to build on the law by lowering costs, expanding coverage, and reducing racial inequities in care.” 

ME AG Aaron Frey, WI AG Josh Kaul, and FL Agricultural Commissioner Nikki Fried to Discuss What Today’s Resounding Decision to Uphold the ACA Means for Millions of Families Nationwide

Today, Protect Our Care will host four press calls with elected officials and health care advocates in Florida, Georgia, Maine, and Wisconsin to react to the Supreme Court decision in California v. Texas, the Trump-Republican lawsuit to overturn the ACA. Today, in an 7-2 ruling, the Supreme Court delivered a massive repudiation of the Republican war on health care. By throwing the lawsuit out on standing, the court protected the health care coverage of more than 20 million Americans and prevented more than 135 million people with pre-existing conditions from losing the protections they rely on, and many other key ACA provisions. 

The decision to affirm the ACA should mean the end of the road for Republicans’ endless attacks on the law and increases the momentum behind President Biden’s and the Democratic majorities in Congress to deliver on their health care agenda that voters elected them to enact. 

FLORIDA

WHO:
Florida Agricultural Commissioner Nikki Fried
State Sen. Lori Berman
Dr. Bernard Ashby, Miami cardiologist and state lead for the Committee to Protect Medicare
Michelle Garcia, health care advocate

WHERE: Dial-In: 877-229-8493, PIN: 120558

WHEN: Thursday, June 17 at 2:00 PM ET

GEORGIA

WHO:
State Rep. Erik Allen
Whitney Riggs, Georgians for a Healthy Future
Cindy Pursley, retired CPA who is a three time cancer survivor and relies on the ACA for health insurance

WHERE: Dial In: 877-229-8493; Pin: 118421

WHEN: Thursday, June 17 at 2:00 PM ET

MAINE

WHO:
Maine Attorney General Aaron Frey
State Sen. Heather Sanborn
State Rep. Thom Harnett
Kate Ende, Consumers for Affordable Health Care
Marie Follyattar, Mainers for Accountable Leadership

WHERE: Dial-In: 877-229-8493; Pin: 114927

WHEN: Thursday, June 17 at 3:00 PM ET

WISCONSIN

WHO:
Wisconsin Attorney General Josh Kaul
Wisconsin residents Lillian Cheesman, David Marsteller, and Vik Verma

WHERE: Dial-In: 877-229-8493 (email [email protected] for the required log-in PIN number)

WHEN: Thursday, June 17 at 1:30 PM CT

In Major Repudiation of a Decade of GOP Attacks on American Health Care, Supreme Court Affirms Protections for People With Pre-Existing Conditions, Medicaid Expansion, and Health Care Coverage for More Than 20 Million Americans 

Democrats Now Turn to Building on the ACA to Lower Drug and Premium Costs, Increase Coverage and Reduce Racial Disparities in Care

Washington, DC — Today, in a massive repudiation of the Republican war on health care, the Supreme Court ruled to uphold the Affordable Care Act in California v. Texas, a lawsuit brought by 18 Republican-led states and backed by the Trump administration, seeking to completely dismantle the health care law. By upholding the ACA, the court saved health coverage for more than 20 million Americans and protections for more than 135 million people with pre-existing conditions, along with many more critical provisions. The decision brings to an ignominious close a decade of Republican attacks on American health care and provides significant momentum to efforts by President Biden and Congressional Democrats to build on the health care law by expanding coverage, lowering costs and addressing racial disparities in care and coverage.   

“Today’s decision is a tremendous victory for the American people and a complete repudiation of the Republican war on health care. Republicans have waged a years-long battle to undermine the Affordable Care Act and rip coverage from millions of Americans, and it has cost them Congress and the White House. Today, it was rejected again by the Supreme Court. This decision should represent the dying gasp of the Republican war on health care, but instead they continue to oppose expanding coverage and lowering drug prices,” said Protect Our Care Executive Director Brad Woodhouse. “The ACA is here to stay.”

“After three defeats in the Supreme Court, dozens of failed efforts to repeal the ACA in Congress, and repudiation at the ballot box, it’s time for Republican elected officials to realize the ACA is here to stay. Repeal is dead, the ACA is more popular than ever, and saving lives every day.  Republican, Democratic and Independent voters, in red states and in blue states, want to build on the ACA to lower drug prices and health care premiums, expand coverage and address racial inequities– and that’s what President Biden and Democrats in Congress are planning to do,” said Protect Our Care Chair Leslie Dach. 

HERE TO STAY: U.S. Health Protections A Decade After Passing Of The Affordable Care Act: 

• GAINED: Protections for 135 million Americans with pre-existing conditions. 
• GAINED: Medicaid expansion, which covers 15 million people. 
• GAINED: Nearly 12 million seniors pay less for prescription drugs. 
• GAINED: 2.3 million adult children are able to stay on their parents’ insurance. 
• GAINED: Three million children nationwide gained coverage. 
• GAINED: Insurance companies are banned from charging women 50 percent more than men.
• GAINED: Financial assistance that helps 9 million people purchase health care in the marketplace.
• GAINED: Key support for rural hospitals. 
• GAINED: Ban on insurance companies having lifetime caps on coverage.
• GAINED: Requirements that insurance companies cover prescription drugs and maternity care

Watch the 30-Second Ad Here

Watch the 15-Second Ad Here

Phoenix, AZ — Today, Arizona Alliance for Retired Americans and a local Arizona health care advocate joined Protect Our Care Arizona for a virtual press conference to announce Protect Our Care’s new digital ad in Arizona — part of a seven-figure ad campaign about prescription drug prices. The ad features Beatriz Morrison, a patient storyteller from Phoenix who is struggling to afford her prescriptions. In the ad, Morrison tells her personal story and relays the importance of giving Medicare the power to negotiate with drug companies for lower prices for all Americans. 

“I either have to cut back on a utility or I have to cut back on my groceries,” said Morrison. “Well, right now I’ll be truthful. I’m only taking medication for my heart. I have Lupus. I have Sjögrens. I have Glaucoma. I have Rheumatoid Arthritis. And I’m only taking medication for my heart.”

The ad is part of the national Campaign to Reduce Drug Prices, a grassroots and communications campaign calling for comprehensive legislation to lower drug prices. The ad will run on digital platforms, focusing particularly on older Americans, beginning on June 15. Protect Our Care will continue to run ads and host events both nationally and in 13 key states, including Arizona, throughout the summer.

“I’m angry because Beatriz is not the only one in Arizona and this country that is living like this,” said Saundra Cole, President of the Arizona Alliance for Retired Americans. “It’s not right. The AARA is trying to get the word out to our elected officials that we built this country and we now we can’t even afford our prescriptions. We need our elected officials to protect us and to advocate for us. That’s what we elect them to do. We are just asking that we are able to pay for our own medication.”

“Right now pharmaceutical companies take advantage of Americans who depend on life-saving drugs,” said Brad Woodhouse, Executive Director of Protect Our Care. “We pay three to four times what consumers are paying in other countries. Arizonans support prescription drug reform because they feel the impact of the high costs of their medications firsthand. Giving Medicare the power to negotiate prescription drug prices will make medications more affordable for Arizonans and all Americans. It’s time for Congress to take action on soaring drug prices and help provide families some much-needed relief.”

Script for “Beatriz” (:15): 

I needed a certain medication.

It was $3,000 dollars. For one month’s supply. 

I chose not to take it because I couldn’t.

Medication and insurance needs to be reasonably priced!

Congress needs to act. Get us what we need!

Script for “Beatriz” (:30): 

I needed a certain medication.

It was $3,000 dollars. For one month’s supply.

I chose not to take it because I couldn’t.

I still have to worry about utilities. I still have to worry about groceries.

Medication and insurance needs to be reasonably priced!

We’re at drug companies mercy because they can tell you what a prescription can cost and what it can’t. 

Congress needs to act. Get us what we need!

You can watch the press conference here, and learn more about how the Lower Drug Costs Now Act (H.R. 3) will make prescription drugs more affordable here.

Last week, the FDA approved the sale of an Alzheimer’s drug, Aducanumab, despite mixed results during its clinical trials and remaining questions about dangerous side effects. Coverage continues to confirm that the drug’s price tag of $56,000 a year will have massive consequences for patients, taxpayers, and the entire health care system. 

Millions of seniors are expected to qualify for this medication, but the drug’s price is double the average income of a person on Medicare. Drugs can only help patients if they can afford them. Patients could be left on the hook for thousands of dollars in out-of-pocket costs while they are grappling with a devastating disease. Even the Alzheimer’s Association called the price of the drug “simply unacceptable.” Aducanumab shines a bright light on Big Pharma’s endless greed and the rigged system that allows drugmakers to set prices for drugs without limits. It also demonstrates the urgent need for giving Medicare the power to negotiate for lower prices.

STAT News: Q&A: The CEO Of The Alzheimer’s Association On The Approval Of Aduhelm — And Why Critics Should Stop Dwelling On The Decision. “We believe that the price is unacceptable because we are so concerned that No. 1, it would cause out-of-pocket costs for so many people that would be so high that it would not reach the number of people it otherwise could. And with a price so high, we’re even more concerned that it would drive more inequity in terms of distribution of a treatment we believe will make a difference for people. We want all communities to have access.” [STAT News, 6/16/21]

The Philadelphia Inquirer: Aduhelm, Biogen’s New Alzheimer’s Drug, Won FDA Approval. Now Doctors, Patients, And Insurers Face Tough Decisions About Care And Cost. “The Alzheimer’s Association…this week pronounced Biogen’s proposed price — a whopping $56,000 a year — ‘simply unacceptable’ and said it would be an ‘insurmountable barrier’ to access. It called for a price cut.” [The Philadelphia Inquirer, 6/15/21]

Politico: New Alzheimer’s Drug Could Be ‘Devastating’ For Medicare. “The $56,000 annual price tag of Biogen’s new drug, Aduhelm, already threatens to balloon health care costs. Coverage from Medicare would undoubtedly mean higher premiums for 56 million older adults, and some experts say the federal government shouldn’t cover the drug given the scant evidence it works.” [Politico, 6/15/21]

STAT News: ‘Simply Unacceptable’: Alzheimer’s Association Blasts Biogen Over The Price Of Its New Medicine. “If [500,000] beneficiaries are prescribed Aduhelm…total spending for Aduhelm in one year would be nearly $29 billion. ‘To put this $29 billion amount in context, total Medicare spending for all Part B drugs was $37 billion in 2019’.” [STAT News, 6/12/21]

The Atlantic: The Drug That Could Break American Health Care. “Aduhelm is likely to increase the federal deficit, squeeze state budgets, and force additional costs onto seniors—all for a drug that may not work.” [The Atlantic, 6/11/21]

NPR: Medicare Copays For New Alzheimer’s Drug Could Reach $11,500. “At this price, the cost of this one drug alone could top all others covered by Medicare, if it is used widely.” [NPR, 6/10/21]

Kaiser Family Foundation: FDA’s Approval Of Biogen’s New Alzheimer’s Drug Has Huge Cost Implications For Medicare and Beneficiaries. “If 1 million Medicare beneficiaries receive Aduhelm, which may even be on the low end of Biogen’s expectations, spending on Aduhelm alone would exceed $57 billion dollars in a single year – far surpassing spending on all other Part B-covered drugs combined.” [Kaiser Family Foundations, 6/10/21]

Bloomberg (Opinion): Alzheimer’s Drug Furor Highlights U.S. Health System’s Failures. “Biogen plans to price the drug at $56,000 a year for the average patient, it also stands to cost Medicare and other insurers a bundle.” [Bloomberg Opinion, 6/10/21]

Endpoints News: What Does A Clear Majority Of The Biopharma Industry Think Of The FDA Approval Of Aducanumab? ‘Horrifying’ ‘Dangerous’ ‘Confusing’ ‘Disaster’. “It became immediately apparent that the vast majority of our readers — heavily concentrated among biopharma staffers and execs — were incensed by what they had just witnessed. [Endpoints News, 6/9/21]

Boston Globe: What’s Next For The New Alzheimer’s Drug? Lots Of Thorny Issues Ahead. “Some consumers may face hefty out-of-pocket charges, which could make them think twice about taking a drug with known risks and uncertain benefits.” [Boston Globe, 6/9/21]

Health Affairs (Blog): Limiting Coverage Based On Efficacy And Safety: A Path Forward For Medicare Regarding The Alzheimer’s Treatment Aducanumab. “It is estimated to cost as much as $70,000 per year, but based on the divide of the drug’s clinical effectiveness, it would need to be priced between $2,500-$8,300 a year to be cost effective and the scientific community ha[s] voiced serious concerns about coverage.” [Health Affairs, 6/7/21] 

***MEDIA ADVISORY FOR WEDNESDAY JUNE 16, 11:00 AM MT // 2:00 PM ET***

Protect Our Care and Arizona Advocates to Announce First Ad in Seven-Figure Campaign Featuring Patient Who Needs Action To Lower Drug Prices

Phoenix, AZ — On Wednesday, June 16 at 11:00 AM MT // 2:00 PM ET, Arizona Alliance for Retired Americans and a local Arizona advocate will join Protect Our Care Arizona for a virtual press conference to announce Protect Our Care’s new digital ad in Arizona — part of a seven-figure ad campaign about prescription drug prices. The ad features Beatriz, a patient storyteller from Phoenix who is struggling to afford her prescriptions. In the ad, Beatriz tells her personal story and relays the importance of giving Medicare the power to negotiate with drug companies for lower prices for all Americans. 

The ad is part of The Campaign to Reduce Drug Prices, a grassroots and communications campaign calling for comprehensive legislation to lower drug prices. The ad will run on digital platforms, focusing particularly on older Americans, beginning on June 15. Protect Our Care will continue to run ads and host events both nationally and in 13 key states, including Arizona, throughout the summer.

WHO:
Beatriz Morrison, Arizonan and Rx drug storyteller
Saundra Cole, Executive Director, Arizona Alliance for Retired Americans
Brad Woodhouse, Executive Director of Protect Our Care
Protect Our Care Arizona

WHAT: Virtual Press Conference 

WHEN: Wednesday, June 16, 2021 at 11:00 AM MT // 2:00 PM ET

WHERE: Register for the Event Here

Protect Our Care Releases New Fact Sheet Debunking Big Pharma’s Claims

As part of Week 2 of Lower Rx Summer, Protect Our Care is releasing a new fact sheet pushing back on Big Pharma’s lies about drug pricing reform. The fact sheet breaks down three major claims pushed by drugmakers and Republican lawmakers to block legislation to reduce prices, including Democrats’ Lower Drug Costs Now Act (H.R. 3) which gives Medicare the power to negotiate for lower drug prices for all Americans. 

Protect Our Care recently announced Lower Rx Summer as part of The Campaign to Reduce Drug Prices. Lower Rx Summer consists of themed weeks of action to demonstrate the urgent need for legislation to lower drug prices principally by giving Medicare the power to negotiate with drug companies for lower prices for all Americans. 

Remaining Theme Weeks for Lower Rx Summer

Week 2 (June 14): Pushing Back on Big Pharma’s Lies

Week 3 (June 21): How High Drug Prices Hurt Seniors

Week 4 (June 28): How High Drug Prices Hurt Women

Week 5 (July 5): How High Drug Prices Hurt People with Disabilities

Week 6 (July 12): How High Drug Prices Hurt People of Color

Week 7 (July 19): How High Drug Prices Hurt Small Businesses

Week 8 (July 26): How High Drug Prices Hurt Children

Fact Sheet: Myth Versus Fact: Big Pharma Scare Tactics

As Big Pharma prepares to fight upcoming legislation to lower drug prices, it is ramping up some of its most powerful scare tactics. In reality, the current system is broken: drug companies experience the highest profits of any major industry while nearly one in four Americans report that they struggle to afford prescribed medications. Drug companies raise the price of existing drugs like insulin year after year, with no reason other than that they can. Americans pay three times more for medicines than people in other countries, and millions are forced to choose between paying for the medications they need and paying for essentials like food and rent. 

Big Pharma, on the other hand, is enjoying sky-high profits and breaking records for the money it’s spending on K Street lobbyists to block any meaningful reform. Here are some of the myths Big Pharma and its Republican allies are pushing: 

MYTH: REDUCING DRUG PRICES WILL HARM INNOVATION, LIKE THE RAPID DEVELOPMENT OF THE COVID-19 VACCINE

FACTS: 

• Higher profits do not correspond with increased research & development. Drug companies saved billions thanks to former President Trump’s tax bill. Instead of making meaningful investments in research and development, drug companies rewarded their executives and shareholders. 
• Price hikes rarely correspond with increased clinical value. Year after year, drug companies hike the prices of existing drugs like insulin without any added benefit to patients. 
• Taxpayers subsidize the creation of new drugs. Americans are being charged twice for high drug costs: first, as taxpayers funding research and development, and then again at the pharmacy counter. 
• The development of COVID-19 vaccines were largely funded by taxpayers, not pharmaceutical companies. More than $19 billion in government funding has been invested in COVID-19 vaccines. Meanwhile, the drugmakers behind the vaccines are spending record amounts of money on lobbying efforts to block reform. 

MYTH: H.R. 3 WILL MAKE THE U.S. RELIANT ON OTHER COUNTRIES

FACTS: 

• Americans pay more for prescription drugs than anyone in the world. On average, Americans pay nearly three times more for medications than people in 32 other countries. 
• CBO found that H.R. 3 would only have a small impact on new drugs coming to the market. The Congressional Budget Office (CBO) analyzed the impact of a decrease of pharmaceutical revenue as much as $1 trillion and found that it would only have a modest impact on drugs coming to market. The CBO found that the U.S. could lose only eight of the 300 new drugs expected in the next decade, and only one or two of which represent “true therapeutic advancements,” per Patients for Affordable Drugs. 

MYTH: H.R. 3 IS GOVERNMENT OVERREACH AND WILL LEAD TO SOCIALIZED HEALTH CARE & DRUG RATIONING

FACTS: 

• Drugs don’t work if patients can’t afford them. Millions of Americans report struggling to afford prescribed medications, forcing them to cut pills in half or skip doses altogether. A 2017 report from the National Academies of Medicine on lowering costs and protecting innovation concluded, “drugs that are not affordable are of little value.”
• Drug companies could lose $1 trillion in sales and still be the most profitable industry. Researchers from West Health Policy Center and Johns Hopkins Bloomberg School of Public Health have found that drug companies could lose $1 trillion in sales and still be the most profitable industry. 

U.S. Rep. Jan Schakowsky Joined Protect Our Care To Urge Lawmakers To Stand Up To Big Pharma and Give Medicare the Power to Negotiate for Lower Drug Prices

Watch the Event Here

Washington D.C.– Today, Representative Jan Schakowsky (D-IL-09) and Dr. Richard Frank of Harvard Medical School joined Protect Our Care for a press call to push back on Big Pharma’s lies and call on Congress to act to bring down the price of prescription drugs. The event was part of Week 2 of Lower Rx Summer, which is focusing on debunking Big Pharma’s most powerful scare tactics. Big Pharma has been spending record amounts on lobbying to deceive the American people and protect its profits as President Biden and members of Congress finally have the opportunity to meaningfully lower drug prices.

In 2019, the House of Representatives passed the Lower Drug Costs Now Act (H.R. 3), bold legislation to give Medicare the power to negotiate for lower prices — the single most effective measure to bring down drug costs for patients. In April, House Democrats reintroduced this legislation, giving Congress another opportunity to lower prescription drug prices and meet the demands of voters across the political spectrum. Nine out of 10 Americans agree that Medicare should have the power to negotiate for lower drug prices for all Americans. Seniors, women, children, communities of color, and everyone purchasing prescription drugs would benefit from this legislation. 

Throughout the week, Protect Our Care will continue to host events and release research to push back on Big Pharma’s biggest lies. Protect Our Care recently announced Lower Rx Summer as part of The Campaign to Reduce Drug Prices. Lower Rx Summer consists of themed weeks of action to demonstrate the urgent need for legislation to lower drug prices principally by giving Medicare the power to negotiate for lower prices. 

“We need to mobilize people to say to Big Pharma, ‘No, we are not going to die rather than get the drugs that we need at a price that we can afford.’ Because that is absolutely what is happening right now,” said Rep. Jan Schakowsky (D-IL-09). “Big Pharma claims that they are spending all this money on research and development, but the fact of the matter is that the price is not set based on how much things cost. Prices are set by how much drug companies want to pay for executive salaries, spend on advertising, and to make more profits. The American people are behind us, and we must get this legislation passed.” 

“There are many drugs out there that come onto the market every year and offer very few, if any, therapeutic benefits, said Dr. Richard Frank, Margaret T. Morris Professor of Health Economics at Harvard Medical School. “I’ve recently done some research which showed that about 40% of the drugs that come on the market offer a few if any new health benefits to American consumers, yet they fetch a fairly substantial price. The new Alzheimer’s drug, Aducanumab, highlights this point: The drug addresses a dreadful disease, but it remains very uncertain how much it’s going to contribute to the well-being and functioning of most people that take it. Priced at $56,000, Aducanumab underscores the disconnect between prices and the value of treatments.” 

“Americans pay more for drugs than anyone in the world. It’s time to put an end to Big Pharma’s rigged system that allows drug companies to charge astronomical prices for medications all while raking in record profits and lining executives’ pockets,” said Protect Our Care Chair Leslie Dach. “Drug companies are well aware that President Biden and Democrats in Congress are determined to take action, so they’ve been ramping up their scare tactics and lobbying efforts. We know the truth: Big Pharma’s claims are nothing short of lies, and the American people are demanding reform. It’s time to give Medicare the power to negotiate for lower drug prices.” 

BACKGROUND:

Fact Sheet: Taking Action To Reduce Drug Prices Will Not Harm Innovation

Remaining Theme Weeks for Lower Rx Summer

Week 2 (June 14): Pushing Back on Big Pharma’s Lies

Week 3 (June 21): How High Drug Prices Hurt Seniors

Week 4 (June 28): How High Drug Prices Hurt Women

Week 5 (July 5): How High Drug Prices Hurt People with Disabilities

Week 6 (July 12): How High Drug Prices Hurt People of Color

Week 7 (July 19): How High Drug Prices Hurt Small Businesses

Week 8 (July 26): How High Drug Prices Hurt Children